|
Luye Pharma Group Ltd. is an international pharmaceutical company focused on the research, production, and marketing of drugs. The company operates in three primary therapeutic areas: oncology, central nervous system (CNS), and cardiovascular system. Key products include Baituowei (goserelin microspheres) for prostate and breast cancer, Zepzelca (lurbinectedin) for small cell lung cancer, Ruoxinlin (Toludesvenlafaxine Hydrochloride) for major depressive disorder, and ERZOFRI (paliperidone palmitate) for psychiatric conditions. The group develops next-generation candidates such as LY03015, LY03017, and LY03020, alongside biologics from its subsidiary Boan Biotech, including BA1106 and BA1302. Luye Pharma serves markets in multiple countries and regions worldwide, with a significant presence in the PRC and the United States. Strategic partnerships include collaborations with Sinopharm, Shanghai Pharmaceutical, King-Friend, Kexing Biopharm, and Nhwa Pharmaceutical for commercialization and distribution. The company also partners with Jitai Technology for AI-driven drug delivery innovation. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Drug Manufacturers - General | Homepage luye.cn |
| Sector Healthcare | IR page — | |
|
Tags
oncology, central nervous system, cardiovascular, innovative drugs, biologics, antibodies, adc drugs, mrna vaccines, long-acting injectables, ai drug delivery, Baituowei, Zepzelca, Ruoxinlin, ERZOFRI, Mimeixin, LY03015, LY03017, LY03020, LY01620, BA1106, BA1302, BA1203, BA2201, BA1304, Boan Biotech, Nhwa Pharmaceutical, Sinopharm, SINOPHARM (CNCM LTD), Shanghai Pharmaceutical, King-Friend, Kexing Biopharm, Jitai Technology
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 5.79B |
| Market cap (USD) | $ 737.886M |
| P/E | 8.15 |
| PEG | 10.69 |
| P/BV | 0.27 |
| P/S | 0.80 |
| P/OCF | 11.18 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 1.4% |
| Returns | |
|---|---|
| ROE | 3.6% |
| ROI | 2.5% |
| ROIC | 2.5% |
| Profit margin | 9.8% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | 0.76% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 52.1% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 12.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.308B | 6.061B | 6.143B | 5.982B | 5.2B | 5.54B | 6.358B | 5.173B | 3.815B | 2.918B | 2.563B | 2.544B | 2.515B |
| Net profit | 618.747M | 471.886M | 532.605M | 604.807M | -134.392M | 706.586M | 1.469B | 1.303B | 981.372M | 891.539M | 754.523M | 605.524M | 310.498M |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpAnnouncements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Luye Pharma Group Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.04% | 276,500 | $ 54.256K | Nov 16, 2026 |
| AVES | 0.03% | 1,884,000 | $ 369.685K | Nov 16, 2026 |
| DFEV | 0.02% | 1,673,500 | $ 348.795K | Nov 12, 2026 |
| DFSE | 0.01% | 292,000 | $ 60.859K | Nov 12, 2026 |
| AVEM | 0.01% | 16,503,000 | $ 3.238M | Nov 16, 2026 |
| DFEM | 0.01% | 3,694,500 | $ 770.016K | Nov 12, 2026 |
| DFAE | 0.00% | 2,142,000 | $ 446.441K | Nov 12, 2026 |
| DFAX | 0.00% | 248,000 | $ 51.689K | Nov 12, 2026 |
| AVSE | 0.00% | 24,000 | $ 4,709.36 | Nov 16, 2026 |